ERBB2 and breast carcinoma: Several in vitro studies suggested that HER2 overexpression can facilitate both the genomic and non-genomic action of ER and its coactivator AIB1 in breast cancer cells, leading to tamoxifen resistance (Chung et al. 2002, Shou et al. 2004).